Patents Assigned to Intezyne Technologies, Inc.
  • Patent number: 11230568
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: January 25, 2022
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEM
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 10857147
    Abstract: The present invention provides SN-38 compositions for treating cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Adam Carie
  • Patent number: 10329326
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 25, 2019
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 10047197
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 14, 2018
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Adam Carie
  • Patent number: 9944752
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 17, 2018
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie, Joseph Edward Semple, Hooshmand Sheshbaradaran
  • Patent number: 9944754
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: April 17, 2018
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Joseph Edward Semple, Tomas Vojkovsky
  • Patent number: 9499665
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: November 22, 2016
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie
  • Patent number: 9441013
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 13, 2016
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 9089578
    Abstract: Methods and compositions for treating neuroendocrine tumors are disclosed.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: July 28, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Hooshmand Sheshbaradaran, William McCulloch
  • Patent number: 9078930
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 14, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie
  • Patent number: 8980326
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: March 17, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Publication number: 20140302607
    Abstract: The present invention provides a methodology for transfecting cells in vitro. In particular, cationic polymers and polynucleotide containing polyplexes comprising such polymers are provided.
    Type: Application
    Filed: January 27, 2014
    Publication date: October 9, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventor: Janni Mirosevich
  • Publication number: 20140271885
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 18, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Tomas Vojkovsky
  • Patent number: 8779008
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: July 15, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
  • Patent number: 8747904
    Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: June 10, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Janni Mirosevich, Gregoire Cardoen, Kevin N. Sill, Habib Skaff
  • Publication number: 20140127271
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: September 16, 2013
    Publication date: May 8, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Hooshmand Sheshbaradaran
  • Publication number: 20140112873
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Application
    Filed: May 17, 2012
    Publication date: April 24, 2014
    Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, INTEZYNE TECHNOLOGIES INC.
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Publication number: 20140113879
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: September 16, 2013
    Publication date: April 24, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventors: Adam Carie, Kevin Sill
  • Publication number: 20140114051
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: September 16, 2013
    Publication date: April 24, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventor: Joseph Edward Semple
  • Patent number: 8629186
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: January 14, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doris